Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001493152-25-005199
Filing Date
2025-02-06
Accepted
2025-02-06 16:15:19
Documents
17
Period of Report
2024-10-31

Document Format Files

Seq Description Document Type Size
1 formdef14a.htm   iXBRL DEF 14A 477064
2 def14a_001.jpg GRAPHIC 27011
3 def14a_002.jpg GRAPHIC 25181
  Complete submission text file 0001493152-25-005199.txt   1135516

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE anix-20241031.xsd EX-101.SCH 5058
5 XBRL DEFINITION FILE anix-20241031_def.xml EX-101.DEF 7961
6 XBRL LABEL FILE anix-20241031_lab.xml EX-101.LAB 62048
7 XBRL PRESENTATION FILE anix-20241031_pre.xml EX-101.PRE 43675
19 EXTRACTED XBRL INSTANCE DOCUMENT formdef14a_htm.xml XML 99583
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: DEF 14A | Act: 34 | File No.: 001-37492 | Film No.: 25597573
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)